NDI draft guidance continues to inform FDA's enforcement thinking, latest DMBA warning letter shows
The Food and Drug Administration is continuing enforcement actions based on the precepts laid out in the draft guidance on New Dietary Ingredients with a warning letter sent to a company marketing a product that contains the stimulant-like ingredient DMBA.